{"id":342427,"date":"2026-11-07T11:12:25","date_gmt":"2026-11-07T05:42:25","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/"},"modified":"2026-11-07T11:12:25","modified_gmt":"2026-11-07T05:42:25","slug":"suven-pharmaceuticals-q2-results-fy27-pat-13-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/","title":{"rendered":"Suven Pharmaceuticals Q2 Results FY27: Profit Falls 82.09%, Revenue Rs 416.69 Cr, PAT Rs 13.27 Cr"},"content":{"rendered":"<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Suven Pharmaceuticals Q2 Results FY27 were declared on 6 November 2026 on a Standalone basis. The quarterly results show revenue of Rs 416.69 Cr, down 25% from Rs 555.57 Cr in the same quarter last year. Net profit stood at Rs 13.27 Cr against Rs 74.08 Cr a year earlier, so YoY growth in net profit was negative 82.09%.<\/p>\n<\/div>\n<p><a href=\"https:\/\/univest.in\/stocks\/cohance\/suven-pharmaceuticals-ltd-share-price-today\">Suven Pharmaceuticals Ltd<\/a> (COHANCE) Q2 Results FY27 announced on 6 November 2026, covering the company&#8217;s financial performance for the July to September quarter. Revenue was Rs 416.69 Cr and net profit (PAT) was Rs 13.27 Cr. The results date and the Standalone basis are stated in every figure below, and Suven Pharmaceuticals Q2 Results FY27 are read against the same quarter of last year.<\/p>\n<p>This results analysis of Suven Pharmaceuticals Q2 Results covers the financial highlights, business factors, outlook and risks behind the quarter. Univest tracks these declared figures for readers who compare filings, so the Financial Highlights section below places revenue and net profit side by side with the year earlier numbers.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=quarterly_results\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Suven_Pharmaceuticals_Q2_Results_FY27_Financial_Highlights\" title=\"Suven Pharmaceuticals Q2 Results FY27: Financial Highlights\">Suven Pharmaceuticals Q2 Results FY27: Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Key_Takeaways_from_Suven_Pharmaceuticals_Q2_Results_What_Stands_Out\" title=\"Key Takeaways from Suven Pharmaceuticals Q2 Results: What Stands Out\">Key Takeaways from Suven Pharmaceuticals Q2 Results: What Stands Out<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Suven_Pharmaceuticals_Q2_Results_FY27_Performance_Analysis\" title=\"Suven Pharmaceuticals Q2 Results FY27: Performance Analysis\">Suven Pharmaceuticals Q2 Results FY27: Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Key_Business_Factors_This_Quarter\" title=\"Key Business Factors This Quarter\">Key Business Factors This Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#FY27_Outlook_After_Suven_Pharmaceuticals_Q2_Results\" title=\"FY27 Outlook After Suven Pharmaceuticals Q2 Results\">FY27 Outlook After Suven Pharmaceuticals Q2 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Key_Risks_to_Watch_After_Suven_Pharmaceuticals_Q2_Results_FY27\" title=\"Key Risks to Watch After Suven Pharmaceuticals Q2 Results FY27\">Key Risks to Watch After Suven Pharmaceuticals Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Revenue_Declined_25_YoY\" title=\"Revenue Declined 25% YoY\">Revenue Declined 25% YoY<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Net_Profit_Fell_8209_YoY\" title=\"Net Profit Fell 82.09% YoY\">Net Profit Fell 82.09% YoY<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Net_Profit_Margin_and_Return_on_Equity\" title=\"Net Profit Margin and Return on Equity\">Net Profit Margin and Return on Equity<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Frequently_Asked_Questions_on_Suven_Pharmaceuticals_Q2_Results_FY27\" title=\"Frequently Asked Questions on Suven Pharmaceuticals Q2 Results FY27\">Frequently Asked Questions on Suven Pharmaceuticals Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#What_are_Suven_Pharmaceuticals_Q2_Results_FY27\" title=\"What are Suven Pharmaceuticals Q2 Results FY27?\">What are Suven Pharmaceuticals Q2 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#What_is_the_results_date_for_Suven_Pharmaceuticals_Q2_Results_FY27\" title=\"What is the results date for Suven Pharmaceuticals Q2 Results FY27?\">What is the results date for Suven Pharmaceuticals Q2 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#What_revenue_was_reported_in_Suven_Pharmaceuticals_Q2_Results_FY27\" title=\"What revenue was reported in Suven Pharmaceuticals Q2 Results FY27?\">What revenue was reported in Suven Pharmaceuticals Q2 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#What_net_profit_was_reported_in_Suven_Pharmaceuticals_Q2_Results_FY27\" title=\"What net profit was reported in Suven Pharmaceuticals Q2 Results FY27?\">What net profit was reported in Suven Pharmaceuticals Q2 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#How_much_YoY_growth_did_revenue_show_in_Suven_Pharmaceuticals_Q2_Results_FY27\" title=\"How much YoY growth did revenue show in Suven Pharmaceuticals Q2 Results FY27?\">How much YoY growth did revenue show in Suven Pharmaceuticals Q2 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Did_net_profit_rise_or_fall_in_Suven_Pharmaceuticals_Q2_Results\" title=\"Did net profit rise or fall in Suven Pharmaceuticals Q2 Results?\">Did net profit rise or fall in Suven Pharmaceuticals Q2 Results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#What_was_the_net_profit_margin_in_Suven_Pharmaceuticals_Q2_Results_FY27\" title=\"What was the net profit margin in Suven Pharmaceuticals Q2 Results FY27?\">What was the net profit margin in Suven Pharmaceuticals Q2 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Are_Suven_Pharmaceuticals_Q2_Results_consolidated_results_or_standalone_results\" title=\"Are Suven Pharmaceuticals Q2 Results consolidated results or standalone results?\">Are Suven Pharmaceuticals Q2 Results consolidated results or standalone results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#What_business_factors_shaped_Suven_Pharmaceuticals_Q2_Results_FY27\" title=\"What business factors shaped Suven Pharmaceuticals Q2 Results FY27?\">What business factors shaped Suven Pharmaceuticals Q2 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#What_are_the_key_risks_after_Suven_Pharmaceuticals_Q2_Results_FY27\" title=\"What are the key risks after Suven Pharmaceuticals Q2 Results FY27?\">What are the key risks after Suven Pharmaceuticals Q2 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#What_is_the_outlook_after_Suven_Pharmaceuticals_Q2_Results\" title=\"What is the outlook after Suven Pharmaceuticals Q2 Results?\">What is the outlook after Suven Pharmaceuticals Q2 Results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-q2-results-fy27-pat-13-crore\/#Where_can_I_find_the_complete_Suven_Pharmaceuticals_Q2_Results_FY27_data\" title=\"Where can I find the complete Suven Pharmaceuticals Q2 Results FY27 data?\">Where can I find the complete Suven Pharmaceuticals Q2 Results FY27 data?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Suven_Pharmaceuticals_Q2_Results_FY27_Financial_Highlights\"><\/span><strong>Suven Pharmaceuticals Q2 Results FY27: Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q2 FY27 (Sep 26)<\/th>\n<th>Q2 FY26 (Sep 25)<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<tr>\n<td><strong>Revenue<\/strong><\/td>\n<td>Rs 416.69 Cr<\/td>\n<td>Rs 555.57 Cr<\/td>\n<td>-25% YoY<\/td>\n<\/tr>\n<tr>\n<td><strong>Net Profit (PAT)<\/strong><\/td>\n<td>Rs 13.27 Cr<\/td>\n<td>Rs 74.08 Cr<\/td>\n<td>-82.09% YoY<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Source: company filing for Suven Pharmaceuticals Q2 Results FY27, 6 November 2026. Figures in Rs Crore, Standalone basis.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Takeaways_from_Suven_Pharmaceuticals_Q2_Results_What_Stands_Out\"><\/span><strong>Key Takeaways from Suven Pharmaceuticals Q2 Results: What Stands Out<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Revenue fell 25% YoY:<\/strong> Revenue came in at Rs 416.69 Cr this quarter, against Rs 555.57 Cr in the same quarter of the previous year.<\/li>\n<li><strong>Net profit fell 82.09% YoY:<\/strong> PAT was Rs 13.27 Cr compared with Rs 74.08 Cr a year earlier, a sharp negative reading on YoY growth.<\/li>\n<li><strong>Profit moved by more than revenue:<\/strong> Suven Pharmaceuticals Q2 Results FY27 show net profit down 82.09% while revenue is down 25%, a gap that follows directly from the supplied figures.<\/li>\n<li><strong>Net profit margin narrowed:<\/strong> It stood at 3.2% this quarter against 13.3% in the comparison quarter, based on the declared revenue and net profit.<\/li>\n<li><strong>Balance sheet marker:<\/strong> The company is almost debt free, with a debt-to-assets ratio of 0.04 in FY26, and return on equity was 4.02% in FY26.<\/li>\n<li><strong>Next step:<\/strong> The performance analysis below shows how revenue and net profit connect across the quarter.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Suven_Pharmaceuticals_Q2_Results_FY27_Performance_Analysis\"><\/span><strong>Suven Pharmaceuticals Q2 Results FY27: Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Suven Pharmaceuticals Q2 Results FY27 show Standalone revenue of Rs 416.69 Cr for July to September 2026, against Rs 555.57 Cr a year earlier, a fall of 25% YoY. Net profit was Rs 13.27 Cr against Rs 74.08 Cr, down 82.09% YoY. Both lines are lower than the same quarter of last year.<\/p>\n<p>The gap between the two moves is visible in the arithmetic. Revenue fell by Rs 138.88 Cr, while net profit fell by Rs 60.81 Cr, so the decline in profit is larger in percentage terms. This results analysis also shows net profit at 3.2% of revenue now against 13.3% in the comparison quarter.<\/p>\n<p>Investors following YoY growth will watch later quarterly results, because one quarter does not set the full year. The declared numbers confirm what changed in revenue and net profit, but they do not establish the specific cause. Suven Pharmaceuticals Q2 Results on a Standalone basis therefore lead into the business factors, which is where the results analysis turns next.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live results data<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_This_Quarter\"><\/span><strong>Key Business Factors This Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Almost Debt Free<\/strong> &#8211; The results analysis points to a balance sheet marker among the business factors: the company is almost debt free, with a debt-to-assets ratio of 0.04 in FY26. Suven Pharmaceuticals Q2 Results FY27 therefore sit alongside a very low level of debt against assets.<\/p>\n<p><strong>Debt-to-Assets Ratio of 0.04<\/strong> &#8211; A ratio of 0.04 in FY26 means debt was a very small share of total assets. This is a disclosed factor for the quarterly results, stated as a fact about the balance sheet rather than as the cause of the revenue or net profit change.<\/p>\n<p><strong>Reading the Factor Against the Numbers<\/strong> &#8211; The disclosed factor does not explain why revenue fell 25% YoY or why net profit fell 82.09% YoY, so it is context for the quarter and not a stated driver. The outlook section covers what this means for FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook_After_Suven_Pharmaceuticals_Q2_Results\"><\/span><strong>FY27 Outlook After Suven Pharmaceuticals Q2 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This results analysis stays with the declared figures and does not rely on any management guidance. FY27 full-year results will depend on the quarters that follow and on disclosed conditions in the company&#8217;s business. Suven Pharmaceuticals Q2 Results FY27 set the second-quarter base for that comparison.<\/p>\n<p>For net profit, the reference point is Rs 13.27 Cr for July to September 2026 against Rs 74.08 Cr a year earlier. Later FY27 filings will show whether net profit stays near this level or moves again, and the risks below set out what to watch.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Watch_After_Suven_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>Key Risks to Watch After Suven Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Declined_25_YoY\"><\/span><strong>Revenue Declined 25% YoY<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue declined 25.0% year on year to Rs 416.69 Cr in the latest quarter. A further fall in revenue would affect every line below it, so the next filing is the clearest place to check this risk.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Net_Profit_Fell_8209_YoY\"><\/span><strong>Net Profit Fell 82.09% YoY<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net profit fell 82.1% year on year to Rs 13.27 Cr. After Suven Pharmaceuticals Q2 Results FY27, readers can track whether YoY growth in net profit stays negative in later quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Net_Profit_Margin_and_Return_on_Equity\"><\/span><strong>Net Profit Margin and Return on Equity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net profit margin narrowed to 3.2% from 13.3% in the comparison quarter, and return on equity was low at 4.02% in FY26. Both measures are worth tracking in later filings from the company.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track quarterly results as they are declared.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Suven Pharmaceuticals Q2 Results FY27 show Standalone revenue of Rs 416.69 Cr and net profit of Rs 13.27 Cr, both lower than a year ago. These quarterly results record a 25% fall in revenue and an 82.09% fall in net profit. Investors tracking Suven Pharmaceuticals Q2 Results can compare later standalone results on the Univest Screener, and should consult a SEBI-registered advisor before acting.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Suven_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>Frequently Asked Questions on Suven Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_are_Suven_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>What are Suven Pharmaceuticals Q2 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Suven Pharmaceuticals Q2 Results FY27 cover July to September 2026 on a Standalone basis, with revenue of Rs 416.69 Cr and net profit of Rs 13.27 Cr, as the Quick Answer sets out.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_results_date_for_Suven_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>What is the results date for Suven Pharmaceuticals Q2 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The results date for Suven Pharmaceuticals Q2 Results FY27 is 6 November 2026, when the company declared its quarterly results, which means the figures in the Financial Highlights table are tied to that filing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_revenue_was_reported_in_Suven_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>What revenue was reported in Suven Pharmaceuticals Q2 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Suven Pharmaceuticals Q2 Results FY27 report revenue of Rs 416.69 Cr for July to September 2026, compared with Rs 555.57 Cr a year earlier, as shown in the Financial Highlights table.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_net_profit_was_reported_in_Suven_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>What net profit was reported in Suven Pharmaceuticals Q2 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Net profit in Suven Pharmaceuticals Q2 Results FY27 was Rs 13.27 Cr, compared with Rs 74.08 Cr in the same quarter last year, so the Financial Highlights table shows a clear fall.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_much_YoY_growth_did_revenue_show_in_Suven_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>How much YoY growth did revenue show in Suven Pharmaceuticals Q2 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue in Suven Pharmaceuticals Q2 Results FY27 showed YoY growth of negative 25%, a fall from Rs 555.57 Cr to Rs 416.69 Cr, which is explained in the Performance Analysis section.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_net_profit_rise_or_fall_in_Suven_Pharmaceuticals_Q2_Results\"><\/span><strong>Did net profit rise or fall in Suven Pharmaceuticals Q2 Results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Suven Pharmaceuticals Q2 Results show net profit falling 82.09% YoY, from Rs 74.08 Cr to Rs 13.27 Cr, while the Key Takeaways section places this fall next to the 25% revenue decline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_net_profit_margin_in_Suven_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>What was the net profit margin in Suven Pharmaceuticals Q2 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Suven Pharmaceuticals Q2 Results FY27 put net profit margin at 3.2%, against 13.3% in the comparison quarter, which means profit took a smaller share of revenue, as the Key Risks section notes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Are_Suven_Pharmaceuticals_Q2_Results_consolidated_results_or_standalone_results\"><\/span><strong>Are Suven Pharmaceuticals Q2 Results consolidated results or standalone results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Suven Pharmaceuticals Q2 Results are standalone results, with revenue of Rs 416.69 Cr and net profit of Rs 13.27 Cr, and the Standalone basis applies to every figure in the Financial Highlights table.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_business_factors_shaped_Suven_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>What business factors shaped Suven Pharmaceuticals Q2 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The disclosed factor for Suven Pharmaceuticals Q2 Results FY27 is that the company is almost debt free, with a debt-to-assets ratio of 0.04 in FY26, as covered in the Key Business Factors section.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_after_Suven_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>What are the key risks after Suven Pharmaceuticals Q2 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks after Suven Pharmaceuticals Q2 Results FY27 are the 25% revenue fall, the 82.09% net profit fall and the narrower 3.2% net profit margin, which the Key Risks section covers in detail.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_outlook_after_Suven_Pharmaceuticals_Q2_Results\"><\/span><strong>What is the outlook after Suven Pharmaceuticals Q2 Results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> After Suven Pharmaceuticals Q2 Results, FY27 full-year results will depend on later quarters and disclosed conditions, so the Outlook section treats the second quarter as the base for comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_find_the_complete_Suven_Pharmaceuticals_Q2_Results_FY27_data\"><\/span><strong>Where can I find the complete Suven Pharmaceuticals Q2 Results FY27 data?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The complete Suven Pharmaceuticals Q2 Results FY27 data sits in the Financial Highlights table above, while the Univest Screener lets readers compare these quarterly results with later filings and other companies.<\/p>\n<p><script type=\"application\/ld+json\" class=\"faq-schema\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are Suven Pharmaceuticals Q2 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Suven Pharmaceuticals Q2 Results FY27 cover July to September 2026 on a Standalone basis, with revenue of Rs 416.69 Cr and net profit of Rs 13.27 Cr, as the Quick Answer sets out.\"}},{\"@type\":\"Question\",\"name\":\"What is the results date for Suven Pharmaceuticals Q2 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The results date for Suven Pharmaceuticals Q2 Results FY27 is 6 November 2026, when the company declared its quarterly results, which means the figures in the Financial Highlights table are tied to that filing.\"}},{\"@type\":\"Question\",\"name\":\"What revenue was reported in Suven Pharmaceuticals Q2 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Suven Pharmaceuticals Q2 Results FY27 report revenue of Rs 416.69 Cr for July to September 2026, compared with Rs 555.57 Cr a year earlier, as shown in the Financial Highlights table.\"}},{\"@type\":\"Question\",\"name\":\"What net profit was reported in Suven Pharmaceuticals Q2 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Net profit in Suven Pharmaceuticals Q2 Results FY27 was Rs 13.27 Cr, compared with Rs 74.08 Cr in the same quarter last year, so the Financial Highlights table shows a clear fall.\"}},{\"@type\":\"Question\",\"name\":\"How much YoY growth did revenue show in Suven Pharmaceuticals Q2 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue in Suven Pharmaceuticals Q2 Results FY27 showed YoY growth of negative 25%, a fall from Rs 555.57 Cr to Rs 416.69 Cr, which is explained in the Performance Analysis section.\"}},{\"@type\":\"Question\",\"name\":\"Did net profit rise or fall in Suven Pharmaceuticals Q2 Results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Suven Pharmaceuticals Q2 Results show net profit falling 82.09% YoY, from Rs 74.08 Cr to Rs 13.27 Cr, while the Key Takeaways section places this fall next to the 25% revenue decline.\"}},{\"@type\":\"Question\",\"name\":\"What was the net profit margin in Suven Pharmaceuticals Q2 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Suven Pharmaceuticals Q2 Results FY27 put net profit margin at 3.2%, against 13.3% in the comparison quarter, which means profit took a smaller share of revenue, as the Key Risks section notes.\"}},{\"@type\":\"Question\",\"name\":\"Are Suven Pharmaceuticals Q2 Results consolidated results or standalone results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Suven Pharmaceuticals Q2 Results are standalone results, with revenue of Rs 416.69 Cr and net profit of Rs 13.27 Cr, and the Standalone basis applies to every figure in the Financial Highlights table.\"}},{\"@type\":\"Question\",\"name\":\"What business factors shaped Suven Pharmaceuticals Q2 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The disclosed factor for Suven Pharmaceuticals Q2 Results FY27 is that the company is almost debt free, with a debt-to-assets ratio of 0.04 in FY26, as covered in the Key Business Factors section.\"}},{\"@type\":\"Question\",\"name\":\"What are the key risks after Suven Pharmaceuticals Q2 Results FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key risks after Suven Pharmaceuticals Q2 Results FY27 are the 25% revenue fall, the 82.09% net profit fall and the narrower 3.2% net profit margin, which the Key Risks section covers in detail.\"}},{\"@type\":\"Question\",\"name\":\"What is the outlook after Suven Pharmaceuticals Q2 Results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"After Suven Pharmaceuticals Q2 Results, FY27 full-year results will depend on later quarters and disclosed conditions, so the Outlook section treats the second quarter as the base for comparison.\"}},{\"@type\":\"Question\",\"name\":\"Where can I find the complete Suven Pharmaceuticals Q2 Results FY27 data?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The complete Suven Pharmaceuticals Q2 Results FY27 data sits in the Financial Highlights table above, while the Univest Screener lets readers compare these quarterly results with later filings and other companies.\"}}]}<\/script><br \/>\n<script type=\"application\/ld+json\" class=\"news-article-schema\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"NewsArticle\",\"headline\":\"Suven Pharmaceuticals Q2 Results FY27: Profit Falls 82.09%, Revenue Rs 416.69 Cr, PAT Rs 13.27 Cr\",\"description\":\"Suven Pharmaceuticals Q2 Results: Standalone revenue \u20b9416.69 Cr, PAT \u20b913.27 Cr. Check YoY growth and quarterly results analysis in the 6 November 2026 filing.\",\"author\":{\"@type\":\"Organization\",\"name\":\"Univest\"},\"publisher\":{\"@type\":\"Organization\",\"name\":\"Univest\",\"url\":\"https:\/\/univest.in\"},\"about\":{\"@type\":\"Corporation\",\"name\":\"Suven Pharmaceuticals Ltd\"}}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suven Pharmaceuticals Q2 Results FY27: Standalone revenue Rs 416.69 Cr, down 25% YoY, and net profit Rs 13.27 Cr, down 82.09% YoY.<\/p>\n","protected":false},"author":29,"featured_media":342426,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[],"class_list":["post-342427","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["342426"],"rank_math_title":["Suven Pharmaceuticals Q2 Results FY27: PAT Down 82.09% to Rs 13.27 Cr"],"rank_math_description":["Suven Pharmaceuticals Q2 Results: Standalone revenue \u20b9416.69 Cr, PAT \u20b913.27 Cr. Check YoY growth and quarterly results analysis in the 6 November 2026 filing."],"rank_math_focus_keyword":["Suven Pharmaceuticals Q2 Results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/suven-pharmaceuticals-q2-results-fy27-profit-falls-82-09-revenue-rs-416-69-cr.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/342427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=342427"}],"version-history":[{"count":0,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/342427\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/342426"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=342427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=342427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=342427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}